利奈唑胺与万古霉素、庆大霉素、环丙沙星、夫西地酸和利福平联合应用对金黄色葡萄球菌的体外杀菌活性。
In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus.
作者信息
Grohs Patrick, Kitzis Marie-Dominique, Gutmann Laurent
机构信息
Hôpital Européen Georges Pompidou, Paris, France.
出版信息
Antimicrob Agents Chemother. 2003 Jan;47(1):418-20. doi: 10.1128/AAC.47.1.418-420.2003.
Abstract
The in vitro activities of linezolid were determined alone and in combination with vancomycin, ciprofloxacin, gentamicin, fusidic acid, or rifampin against five methicillin-susceptible Staphylococcus aureus (MSSA) and five methicillin-resistant S. aureus (MRSA) strains. Similar responses were obtained against MSSA and MRSA. When combined with fusidic acid, gentamicin, or rifampin, linezolid prevented selection of resistant mutants but showed no synergy. When linezolid was combined with vancomycin and ciprofloxacin, a slight antagonism was observed. While the combination with linezolid may reduce the emergence of mutants resistant to the associated drugs, the absence of synergy, especially in the case of vancomycin and ciprofloxacin, does not argue in favor of such combinations.
摘要
单独测定了利奈唑胺以及利奈唑胺与万古霉素、环丙沙星、庆大霉素、夫西地酸或利福平联合使用时对5株甲氧西林敏感金黄色葡萄球菌（MSSA）和5株甲氧西林耐药金黄色葡萄球菌（MRSA）菌株的体外活性。对MSSA和MRSA获得了相似的反应。当与夫西地酸、庆大霉素或利福平联合使用时，利奈唑胺可防止耐药突变体的产生，但未显示协同作用。当利奈唑胺与万古霉素和环丙沙星联合使用时，观察到轻微拮抗作用。虽然与利奈唑胺联合使用可能会减少对相关药物耐药的突变体的出现，但缺乏协同作用，尤其是在万古霉素和环丙沙星的情况下，并不支持这种联合使用。
相似文献
1
In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus.
Antimicrob Agents Chemother. 2003 Jan;47(1):418-20. doi: 10.1128/AAC.47.1.418-420.2003.
2
In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods.
J Antimicrob Chemother. 2003 Apr;51(4):857-64. doi: 10.1093/jac/dkg160. Epub 2003 Mar 13.
3
[Sensitivity of methicillin resistant staphylococci to linezolid and some other antimicrobial agents].
Mikrobiyol Bul. 2003 Oct;37(4):235-40.
4
Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 2004 Dec;48(12):4665-72. doi: 10.1128/AAC.48.12.4665-4672.2004.
5
In-vitro antibacterial activity of fusidic acid alone and in combination with other antibiotics against methicillin-sensitive and -resistant Staphylococcus aureus.
J Antimicrob Chemother. 1994 Dec;34(6):899-907. doi: 10.1093/jac/34.6.899.
6
[Influence of inoculum size on MICs for methicillin-susceptible Staphylococcus aureus and methicillin-resistant Staphylococcus aureus].
Jpn J Antibiot. 2011 Aug;64(4):231-7.
7
Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Eur J Clin Microbiol Infect Dis. 2001 Jul;20(7):486-9. doi: 10.1007/pl00011290.
8
In-vitro effects of vancomycin, rifampicin, and fusidic acid, alone and in combination, against methicillin-resistant Staphylococcus aureus.
J Antimicrob Chemother. 1983 Jan;11(1):21-6. doi: 10.1093/jac/11.1.21.
9
Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.
Antimicrob Agents Chemother. 2009 Mar;53(3):1142-8. doi: 10.1128/AAC.00775-08. Epub 2008 Dec 15.
10
The in-vitro activity of some antimicrobial agents against methicillin-resistant Staphylococcus aureus.
J Antimicrob Chemother. 1985 Mar;15(3):291-5. doi: 10.1093/jac/15.3.291.
引用本文的文献
1
Polymyxin B and fusidic acid, a novel potent synergistic combination against and isolates with polymyxin B resistance.
Front Microbiol. 2023 Oct 11;14:1220683. doi: 10.3389/fmicb.2023.1220683. eCollection 2023.
2
Phenotypic and genotypic characterization of linezolid resistance and the effect of antibiotic combinations on methicillin-resistant Staphylococcus aureus clinical isolates.
Ann Clin Microbiol Antimicrob. 2023 Apr 3;22(1):23. doi: 10.1186/s12941-023-00574-2.
3
The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis.
Antimicrob Resist Infect Control. 2021 May 1;10(1):75. doi: 10.1186/s13756-021-00943-6.
4
Liposomes as a Nanoplatform to Improve the Delivery of Antibiotics into Biofilms.
Pharmaceutics. 2021 Mar 2;13(3):321. doi: 10.3390/pharmaceutics13030321.
5
Efficacy of vancomycin in combination with various antimicrobial agents against clinical methicillin resistant strains.
Pak J Med Sci. 2021 Jan-Feb;37(1):151-156. doi: 10.12669/pjms.37.1.2887.
6
Synergy of Linezolid with Several Antimicrobial Agents against Linezolid-Methicillin-Resistant Staphylococcal Strains.
Antibiotics (Basel). 2020 Aug 9;9(8):496. doi: 10.3390/antibiotics9080496.
7
A new method for biological synthesis of agriculturally relevant nanohydroxyapatite with elucidated effects on soil bacteria.
Sci Rep. 2019 Oct 21;9(1):15083. doi: 10.1038/s41598-019-51514-0.
8
Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in Static and Dynamic Models.
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00598-18. Print 2018 Jul.
9
Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an Model of Simulated Endocardial Vegetations.
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.00101-18. Print 2018 May.
10
activity of recombinant lysostaphin in combination with linezolid, vancomycin and oxacillin against methicillin-resistant .
Iran J Microbiol. 2017 Aug;9(4):208-212.
本文引用的文献
1
In vitro activity of fosfomycin in combination with various antistaphylococcal substances.
J Antimicrob Chemother. 2001 Aug;48(2):209-17. doi: 10.1093/jac/48.2.209.
2
Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2001 Aug;45(8):2304-8. doi: 10.1128/AAC.45.8.2304-2308.2001.
3
Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci.
Antimicrob Agents Chemother. 2001 Jul;45(7):2154-6. doi: 10.1128/AAC.45.7.2154-2156.2001.
4
Linezolid therapy of Staphylococcus aureus experimental osteomyelitis.
Antimicrob Agents Chemother. 2000 Dec;44(12):3438-40. doi: 10.1128/AAC.44.12.3438-3440.2000.
5
Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
Antimicrob Agents Chemother. 1998 Mar;42(3):721-4. doi: 10.1128/AAC.42.3.721.
6
Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions.
Antimicrob Agents Chemother. 1997 Oct;41(10):2132-6. doi: 10.1128/AAC.41.10.2132.
7
In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species.
Antimicrob Agents Chemother. 1997 Feb;41(2):465-7. doi: 10.1128/AAC.41.2.465.
8
In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis.
Antimicrob Agents Chemother. 1996 Oct;40(10):2428-30. doi: 10.1128/AAC.40.10.2428.
9
In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.
Antimicrob Agents Chemother. 1996 Mar;40(3):799-801. doi: 10.1128/AAC.40.3.799.
10
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.
Antimicrob Agents Chemother. 1996 Mar;40(3):720-6. doi: 10.1128/AAC.40.3.720.
Zotero 插件